18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer
Crossref DOI link: https://doi.org/10.1186/s40644-017-0125-5
Published Online: 2017-08-03
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Korn, Ronald L.
Von Hoff, Daniel D.
Borad, Mitesh J.
Renschler, Markus F.
McGovern, Desmond
Curtis Bay, R.
Ramanathan, Ramesh K.
Funding for this research was provided by:
Celgene
Stand Up To Cancer